| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OCUL | Common Stock | Sale | -$49.4K | -6.3K | -2.99% | $7.84 | 205K | Jan 31, 2025 | Direct | F1, F2, F3 |
| transaction | OCUL | Common Stock | Sale | -$86.8K | -11.1K | -5.44% | $7.81 | 193K | Feb 4, 2025 | Direct | F4, F5 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 30, 2025. The sales do not represent a discretionary trade by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.68 to $7.97, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| F3 | Includes 1,876 shares of common stock acquired under the 2014 Ocular Therapeutix, Inc. Employee Stock Purchase Plan on December 31, 2024. |
| F4 | Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2025. The sales do not represent a discretionary trade by the reporting person. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $7.88, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form |
Chief Financial Officer and Chief Operating Officer